Full Title
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)Purpose
Researchers want to see how well a new cellular immunotherapy works to treat multiple myeloma. The people in this study have multiple myeloma that keeps growing or came back after treatment.
BMS-986393 is a form of chimeric antigen receptor (CAR) T cell therapy. With CAR T cell therapy, white blood cells called T cells are removed from your body. The T cells are altered in a lab to recognize proteins on your cancer cells. They are then multiplied to larger numbers and returned to your body to find and destroy cancer cells. BMS-986393 is given intravenously (by vein).
Before BMS-986393, you will get the chemotherapy drugs fludarabine and cyclophosphamide to briefly dampen your immune system. This chemotherapy will help prepare your body to receive BMS-986393.
Who Can Join
To join this study, there are a few conditions. You must:
- Have multiple myeloma that came back or keeps growing after at least 3 prior regimens of treatment.
- Have recovered from the serious side effects of prior therapies before getting the study treatment.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Sham Mailankody’s office at 646-608-2091.